Supplementary Materials

Table of contents

[Tables 2](#_Toc70589727)

[Table S1. Results of studies synthesised narratively 2](#_Toc70589728)

[Table S2. Summary of findings: Preterm formula vs Human milk – Weight gain (g/d) 6](#_Toc70589729)

[Table S3. Summary of findings: Preterm formula vs Human milk – Weight gain (g/kg/d) 7](#_Toc70589730)

[Table S4. Summary of findings: Preterm formula vs Human milk – change in weight z-score 8](#_Toc70589731)

[Table S5. Summary of findings: Preterm formula vs Human milk - head circumference gain (cm/wk) 9](#_Toc70589732)

[Table S6. Summary of findings: Preterm formula vs Human milk – change in head circumference z-score 10](#_Toc70589733)

[Table S7. Summary of findings: Preterm formula vs Human milk – length gain (cm/week) 11](#_Toc70589734)

[Table S8. Summary of findings: Preterm formula vs Human milk - change in length z-score 12](#_Toc70589735)

[Table S9. Summary of findings: Preterm formula vs Human milk - % fat-free mass 13](#_Toc70589736)

[Table S10. Summary of findings: Preterm formula vs Human milk - fat-free mass (g) 14](#_Toc70589737)

[Table S11. Summary of findings: Preterm formula vs Human milk - % fat mass 15](#_Toc70589738)

[Table S12. Summary of findings: Preterm formula vs Human milk - fat mass (g) 16](#_Toc70589739)

[Figures 17](#_Toc70589740)

[Figure S1. Prisma diagram – selection of studies 17](#_Toc70589741)

[References 18](#_Toc70589742)

# Tables

## Table S1. Results of studies synthesised narratively

| Study | Variable synthesised narratively | Reason for non-inclusion in meta-analyses | Comparison for this review | Results |
| --- | --- | --- | --- | --- |
| Brownell 2018 [1] | Wt, length and HC gain, change in z-score | Multivariable linear regression models used for associations between feeding and growth. Feeding groups were not mutually exclusive | C3 | Associations between diet composition and growth velocity, using MOM as reference and  10% increases in PTF intake   |  |  |  |  | | --- | --- | --- | --- | |  | Weight gain, g/kg/day  n=313  β (95% CI) | HC growth, cm/wk  n=307  β (95% CI) | Length gain, cm/wk  n=311  β (95% CI) | | Adjusted mean for MOM | 17.08 (12.7, 21.45) | 1.17 (0.75, 1.58) | 3.18 (2.25, 4.11) | | Proportion of diet as DHM | -0.17 (-0.28, -0.05)  P=0.01 | -0.01 (-0.02, -0.001)  P=0.03 | -0.001 (-0.3, 0.03)  P=0.95 | | Proportion of diet as PTF | 0.09 (-0.04, 0.21) P=0.18 | 0.01 (-0.01, 0.020) P=0.23 | -0.01 (-0.05, 0.02) P=0.44 |   Associations between diet composition and growth z-scores, using MOM as reference and  10% increases in PTF intake   |  |  |  |  | | --- | --- | --- | --- | |  | Weight z-score change  n=314  β (95% CI) p | HC z-score change  n=312  β (95% CI) p | Length z-score change  n=298  β (95% CI) p | | Adjusted mean change in z-score for MOM | -0.93 (-1.15, -0.72) | -0.31 (-0.51, -0.10) | -0.12 (-0.62, 0.40) | | Proportion of diet as DHM | -0.04 (-0.06, -0.02)  P <0.001 | -0.06 (-0.10, \_0.02)  P= 0.002 | -0.05 (-0.13, 0.03)  P= 0.22 | | Proportion of diet as PTF | 0.03 (0.01, 0.05)  P= 0.01 | 0.002 (-0.04, 0.04)  P= 0.92 | -0.09 (-0.17, -0.01)  P=0.04 | |
| Castellano Yanez 2019 [2] | Wt, length, HC, change in z-score | Data reported as mean z-score difference over hospital stay between groups | C3 | Mean difference in z-score between higher dose HM (n=78) and lower dose HM (n=52) over hospital stay   |  |  |  | | --- | --- | --- | |  | MD (95% CI) | P | | Weight z-score | -0.104 (-0.175 to -0.032) | 0.004 | | Length z-score | -0.312 (-0.469 to -0.154) | <0.001 | | HC z-score | -0.166 (-0.301 to -0.30) | <0.017 | |
| Carlson 1998 [3] | Wt gain | Growth reported in time periods 0 -14 d, 15 – 35 d, 36 – 56 d, 57 d to TCA and not comparable with other data | C1, C2 & C3 | Wt gain (mean ± SD) according to feeding type   |  |  |  | | --- | --- | --- | | Feeding type | N | Weight gain, g/kg/day | | Age 0 – 14 days |  |  | | EHM | 23 | 1.7 ± 4.9 | | Mixed feeds | 14 | -0.1 ± 4.8 | | EPTF | 14 | 2.4 ± 7.1 | | Age 15 – 35 days1,2 |  |  | | EHM | 23 | 11.5 ± 4.0 | | Mixed feeds | 14 | 13.2 ± 4.4 | | EPTF | 14 | 15.9 ± 3.3 | | Age 36-56 days |  |  | | EHM | 21 | 12.2 ± 3.6 | | Mixed feeds | 13 | 16.0 ± 4.1 | | EPTF | 11 | 14.0 ± 3.2 | | Age 57 days to term1,3 |  |  | | EHM | 15 | 9.9 ± 3.9 | | Mixed feeds | 9 | 11.9 ± 2.8 | | EPTF | 10 | 13.7 ± 4.3 | | 1 EPTF vs EHM P<0.05  2 EPTF vs any HM MD 3.76 g/kg/d, 95% CI 1.57 to 5.95 (not reported in paper – calculated using Revman 4.1)  3 EPTF vs any HM MD 3.05, 95% CI 0.02 to 6.08 (not reported in paper – calculated using Revman 4.1) | | | |
| Hoban 2019 [4] | Wt length and HC z-scores | Data reported as deviation from the reference growth trend for each week (NICU LOS, GA), female sex, and for each 10% increase in proportion of  formula. | C3 | |  |  |  |  | | --- | --- | --- | --- | |  | Weight  (change in z-score)  n=321 | Length  (change in z-score)  n=321 | HC  (change in z-score)  n=321 | |  | Parameter estimate (SE) | Parameter estimate (SE) | Parameter estimate (SE) | | Growth for reference infant1 | -0.216 (0.029)  P <0.0012 | -0.333 (0.027)  P <0.0012 | 0.013 (0.030)  P = 0.6542 | | Proportion formula3 | 0.018 (0.007)  P = 0.0092 | 0.016 (0.006)  P = 0.012 | 0.013 (0.007)  P = 0.0572 |   1 Average monthly change in z-score for reference subjects who received 100% MOM (n=255) at mean NICU LOS, GA and sex.  2 P value testing hypothesis that the change in z-score is zero  3 Deviation from the reference growth trend for each week (NICU LOS GA) female sex and for each 10% increase in proportion of PTF |
| Jacobi-Polishook, 2016 [5] | Body mass index gain | Only study reporting body mass index | C3 | Body mass index gain   |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | |  | Full cohort  n=611 | No HM  n=46 | Quartile 1 HM  n=141 | Quartile 2 HM  n=141 | Quartile 3 HM  n=142 | Quartile 4 HM  n=141 | | BMI gain, birth to discharge (kg/m2/wk) | 0.47 ± 0.20 | 0.52 ± 0.16 | 0.49 ± 0.21 | 0.44 ± 0.24 | 0.44 ± 0.16 | 0.50 ± 0.20 | |
| Kaempf 1998 [6] | Length gain | Measured lower leg length | C3 | Lower leg length growth   |  |  |  | | --- | --- | --- | |  | Fortified HM  n=8 | PTF  n=11 | | Lower leg length growth velocity (mean ± SD mm/d) | 0.51 ± 0.04 | 0.54 ± 0.09 | |
| Li 2019 [7] | Change in wt, length and HC  z-scores  Fat mass (g)  Fat-free mass (g) | Multivariable regression used for association between feed exposure and outcomes. | C3 | Regression analysis of HM intake and growth outcomes   |  |  |  |  | | --- | --- | --- | --- | |  | EHM  n=56 | High dose HM  (predominantly HM)  n=39 | Low dose HM  (predominantly formula)  n= 38 | | Wt z-score change | Reference | 0.2 (−0.2 to 0.6), P=0.32 | 0.6 (0.2 to 0.1), P<0.01 | | Length z-score change | Reference | 0.5 (−0.1 to 1.2), P=0.13 | 0.3 (−0.5 to 1.0), P=0.48 | | HC z-score change | Reference | −0.1 (−0.9 to 0.6), P=0.73 | 0 (−0.9 to 0.8), P=0.94 | | FM, g | Reference | 11.2 (−61.9 to 84.4), P=0.76 | 26.1 (−49.2 to 101.5), P=0.50 | | FFM, g | Reference | 86.1 (−28.8 to 201.1), P=0.14 | 257.4 (139.1 to 375.7), P<0.01 |   Data are adjusted mean difference with 95% CIs compared to reference infant fed EHM (n=56) adjusted for covariates including baseline characteristics, age at imaging, total nutrient intake before 34 weeks PMA, and level of care |
| Manea 2016 [8] | Wt gain | SD not reported | C1 | Weight gain of infants with BW <1kg, within the first 5 weeks of life, according to type of early enteral nutrition given (g/d)   |  |  | | --- | --- | |  | Average wt gain | | EHM (n= 18) | 17.26 | | EPTF (n=16) | 13.89 |   No SD or p values reported |
| Nicholl 1999 [9] | Length gain | Measured lower leg length | C1 | Lower leg length velocity – between group change, mean ± SD   |  |  |  |  | | --- | --- | --- | --- | |  | EHM (Gp2) | EPTF (Gp3) |  | | Lower leg length gain (mm/d) | 0.17 ± 0.38 | 0.28 ± 0.50 | P=0.9 | |
| Soldateli 2020 [10] | Wt gain (g/kg/day), change in weight and length z-scores | SD not reported | C3 | Human milk feeding and growth to discharge or transfer   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | |  | Days fed any HM | | | | | P values | | |  | 0-25% n=40 | 26-50% n=151 | 51-75% n=268 | 76-99% n=375 | All HM n=594 | Across all Groups | Between 0-25% and All HM | | Wt gain, g/kg/d | 13.8 | 13.5 | 13.5 | 13.7 | 13.6 | 0.6 | 0.3 | | Change in wt z-score | -0.6 | -0.7 | -0.7 | -0.6 | -0.7 | 0.7 | 0.2 | | HC gain, cm/wk | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.4 | 0.1 | | Change in HC z-score | -0.1 | -0.3 | -0.4 | -0.3 | -0.3 | 0.8 | 0.2 | | Change in length z-score | -0.9 | -1.3 | -1.3 | -1.2 | -1.1 | 0.09 | 0.2 |   Diet recorded on days of life 7, 14, 21, 28, 42, 56, 70, 84, and at NICU discharge or transfer |
| *Abbreviations:* DHM, donor human milk; EHM, exclusive human milk; EPTF, exclusive preterm formula; GA, gestational age; HC, head circumference; HM, human milk; LOS, length of stay; MD, mean difference; MOM, mother’s own milk; NICU, neonatal intensive care unit; PTF, preterm formula; SD, standard deviation; SE, standard error; Wt, weight | | | | |

## Table S2. Summary of findings: Preterm formula vs Human milk – Weight gain (g/d)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** RCT | - | MD 2 higher  (1.54 lower to 5.54 higher) | - | 53  (1 RCT) | Not graded as only one study. ROB moderate |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design: Observational** | - | MD 0.83 lower  (1.65 lower to 0 ) | - | 1606  (2 observational studies) | ⊕⊕⊝⊝  LOW1 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | |
| 1Observational studies considered low quality evidence | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | |

## Table S3. Summary of findings: Preterm formula vs Human milk – Weight gain (g/kg/d)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 2.03 higher (0.31 lower to 4.38 higher) | - | 364  (4 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| **Intervention:** Exclusive preterm formula  **Comparison:** Any human milk  **Study design:** Observational | - | MD 1.97 higher (0.21 higher to 3.72 higher) | - | 795  (5 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD 2.41 higher (1.09 higher to 3.72 higher) | - | 373  (2 RCTs) | ⊕⊕⊝⊝  LOW 3 4 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.56 higher (0.09 higher to 1.03 higher) | - | 3162 (13 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 5 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  3Downgraded for imprecision  4Downgraded for ROB – one RCT with high ROB, one RCT with low ROB  5Downgraded for inconsistency – substantial heterogeneity (I2 50-74%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S4. Summary of findings: Preterm formula vs Human milk – change in weight z-score

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 0.26 higher (0.03 higher to 0.48 higher) | - | 494 (2 observational studies) | ⊕⊕⊝⊝  LOW 1 |
| **Intervention:** Exclusive preterm formula  **Comparison:** Any human milk  **Study design:** Observational | - | MD 0.21 higher  (0.15 lower to 0.56 higher) | - | 1532 (3 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD 0  (0.29 lower to 0.29 higher) | - | 326  (1 RCT) | Not graded as only one study. ROB low |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.19 higher (0.06 higher to 0.33 higher) | - | 4059 (12 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S5. Summary of findings: Preterm formula vs Human milk - head circumference gain (cm/wk)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** RCT | - | MD 0.1 higher (0.02 lower to 0.22 higher) | - | 53 (1 RCT) | Not graded as only one study. ROB moderate |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 0.09 higher (0.1 lower to 0.29 higher) | - | 78  (2 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| **Intervention:** Exclusive preterm formula  **Comparison:** Any human milk  **Study design:** Observational | - | MD 0.06 higher (0.01 higher to 0.11 higher) | - | 495 (4 observational studies) | ⊕⊕⊝⊝  LOW 1 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD 0 (0.06 lower to 0.06 higher) | - | 373 (2 RCTs) | ⊕⊕⊕⊝  MODERATE 4 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.04 higher  (0.02 higher to 0.07 higher) | - | 4080 (10 observational studies) | ⊕⊝⊝⊝  VERY LOW 5 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  3Downgraded for imprecision  4Downgraded for ROB – one RCT with high ROB, one RCT with low ROB  5Downgraded for inconsistency – substantial heterogeneity (I2 50-74%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S6. Summary of findings: Preterm formula vs Human milk – change in head circumference z-score

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 0.1 higher (0.42 lower to 0.62 higher) | - | 32 (1 observational study) | Not graded as only one study. ROB low |
| **Intervention:** Exclusive preterm formula  **Comparison:** Any human milk  **Study design:** Observational | - | MD 0.43 higher (0.18 higher to 0.69 higher) | - | 322  (2 observational studies) | ⊕⊕⊝⊝  LOW 1 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD 0.2 higher  (0.08 lower to 0.48 higher) | - | 326  (1 RCT) | Not graded as only one study. ROB low |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.09 higher  (0.19 lower to 0.38 higher) | - | 2627  (8 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  3Downgraded for imprecision | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S7. Summary of findings: Preterm formula vs Human milk – length gain (cm/week)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** RCT | - | MD 0.28 higher  (0.14 higher to 0.42 higher) | - | 53  (1 RCT) | Not graded as only one study. ROB moderate |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 0.06 higher  (0.07 lower to 0.19 higher) | - | 78  (2 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| **Intervention:** Exclusive preterm formula  **Comparison:** Any human milk  **Study design:** Observational | - | MD 0.09 higher  (0.05 lower to 0.22 higher) | - | 778  (3 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD -0.04  (0.28 lower to 0.21 higher) | - | 373  (2 RCTs) | ⊕⊕⊝⊝  LOW 1 4 5 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.05 higher  (0.02 higher to 0.08 higher) | - | 2423  (8 observational studies) | ⊕⊕⊝⊝  LOW 1 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for imprecision  3Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  4Downgraded for ROB – one RCT with high ROB, one RCT with low ROB  5Downgraded for inconsistency – substantial heterogeneity (I2 50-74%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S8. Summary of findings: Preterm formula vs Human milk - change in length z-score

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 0  (0.63 lower to 0.63 higher) | - | 32  (1 observational study) | Not graded as only one study. ROB low |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** RCT | - | MD 0.1 higher  (0.26 lower to 0.46 higher) | - | 326  (1 RCT) | Not graded as only one study. ROB low |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.09 higher  (0.07 lower to 0.25 higher) | - | 1131  (3 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  3Downgraded for imprecision | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S9. Summary of findings: Preterm formula vs Human milk - % fat-free mass

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 1.46 lower  (4.35 lower to 1.43 higher) | - | 87  (3 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 5.1 lower  (12.45 lower to 2.25 higher) | - | 73  (1 observational study) | Not graded as only one study. ROB low |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; RCT, randomised controlled trial; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S10. Summary of findings: Preterm formula vs Human milk - fat-free mass (g)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 130.18 higher  (53.86 higher to 206.5 higher) | - | 134  (4 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for imprecision | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S11. Summary of findings: Preterm formula vs Human milk - % fat mass


|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 1.82 higher  (0.59 lower to 4.23 higher) | - | 141  (4 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 |
| **Intervention:** Lower dose human milk  **Comparison:** Higher dose human milk  **Study design:** Observational | - | MD 0.48 lower  (1.7 lower to 0.73 higher) | - | 133  (1 observational study) | Not graded as only one study. ROB low |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference; ROB, risk of bias | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%) | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

## Table S12. Summary of findings: Preterm formula vs Human milk - fat mass (g)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcomes** | **Anticipated absolute effects\* (95% CI)** | | **Relative effect (95% CI)** | **№ of participants (studies)** | **Certainty of the evidence (GRADE)** |
| **Risk with human milk  (exclusive, any or high dose)** | **Risk with preterm formula** |
| **Intervention:** Exclusive preterm formula  **Comparison:** Exclusive human milk  **Study design:** Observational | - | MD 60.94 higher  (5.42 lower to 127.31 higher) | - | 134  (4 observational studies) | ⊕⊝⊝⊝  VERY LOW 1 2 3 |
| \*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). *Abbreviations*: CI, Confidence interval; MD, mean difference | | | | | | |
| 1Observational studies considered low quality evidence  2Downgraded for inconsistency – considerable heterogeneity (I2 75-100%)  3Downgraded for imprecision | | | | | | |
| GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | | | | | | |

# Figures

## Figure S1. Prisma diagram – selection of studies



# References

1. Brownell, E.A.; Matson, A.P.; Smith, K.C.; Moore, J.E.; Esposito, P.A.; Lussier, M.M.; Lerer, T.J.; Hagadorn, J.I. Dose-response relationship between donor human milk, mother's own milk, preterm formula, and neonatal growth outcomes. *J. Pediatr. Gastroenterol. Nutr.* **2018**, *67*, 90-96.

2. Castellano Yáñez, C.; Castillo Barrio, B.; Muñoz Labián, M.D.C.; Ortiz Movilla, R.; García Lara, N.R.; Royuela Vicente, A.; Marín Gabriel, M.A. Providing very preterm infants with donor human milk led to faster breastfeeding rates but worse biometric gains. *Acta. Paediatr.* **2019**, *108*, 766-767.

3. Carlson, S.J.; Ziegler, E.E. Nutrient intakes and growth of very low birth weight infants. *J. Perinatol.* **1998**, *18*, 252-258.

4. Hoban, R.; Schoeny, M.E.; Esquerra-Zwiers, A.; Kaenkumchorn, T.K.; Casini, G.; Tobin, G.; Siegel, A.H.; Patra, K.; Hamilton, M.; Wicks, J.*, et al.* Impact of donor milk on short- and long-term growth of very low birth weight infants. *Nutrients* **2019**, *11*.

5. Jacobi-Polishook, T.; Collins, C.T.; Sullivan, T.R.; Simmer, K.; Gillman, M.W.; Gibson, R.A.; Makrides, M.; Belfort, M.B. Human milk intake in preterm infants and neurodevelopment at 18 months corrected age. *Pediatr. Res.* **2016**.

6. Kaempf, D.E.; Pfluger, M.S.; Thiele, A.M.; Hermanussen, M.; Linderkamp, O. Influence of nutrition on growth in premature infants: Assessment by knemometry. *Ann. Hum. Biol.* **1998**, *25*, 127-136.

7. Li, Y.; Liu, X.; Modi, N.; Uthaya, S. Impact of breast milk intake on body composition at term in very preterm babies: Secondary analysis of the nutritional evaluation and optimisation in neonates randomised controlled trial. *Arch. Dis. Child. Fetal. Neonatal Ed.* **2019**, *104*, F306-f312.

8. Manea, A.; Boia, M.; Iacob, D.; Dima, M.; Iacob, R.E. Benefits of early enteral nutrition in extremely low birth weight infants. *Singapore Med. J.* **2016**, *57*, 616-618.

9. Nicholl, R.M.; Gamsu, H.R. Changes in growth and metabolism in very low birthweight infants fed with fortified breast milk. *Acta. Paediatr.* **1999**, *88*, 1056-1061.

10. Soldateli, B.; Parker, M.; Melvin, P.; Gupta, M.; Belfort, M. Human milk feeding and physical growth in very low-birth-weight infants: A multicenter study. *J. Perinatol.* **2020**, *40*, 1246-1252.